» Articles » PMID: 27772753

Antioxidant and Inflammatory Biomarkers for the Identification of Prodromal Parkinson's Disease

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 2016 Oct 25
PMID 27772753
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We explored the role of oxidative stress and inflammatory molecules as potential Parkinson (PD) biomarkers and correlated biological with non-motor abnormalities (olfactory impairment and dysautonomia), in patients with idiopathic REM behavior disorder (iRBD) (prodromal PD) and established PD.

Methods: We recruited 11 iRBD and 15 patients with idiopathic PD (Hohen&Yahr 1-3, on L-DOPA and dopamine agonists combination therapy) and 12 age- and sex-matched controls (CTRL). We measured total olfactory score (TOS), autonomic function [deep breathing (DB), lying to standing (LS) and Valsalva manoeuvre (VM) ratios], blood reduced glutathione (Br-GSH), oxidative stress and inflammatory markers (neopterin).

Results: Anosmia was similarly prevalent in iRBD (36%) and PD (33%) patients, but absent in CTRL. Orthostatic hypotension was more common among iRBD (73%) and PD (60%) than in CTRL (25%). By univariable ordinal logistic regression, TOS, Br-GSH, LS and VM ratio worsened from CTRL to iRBD and PD groups. Only reduced Br-GSH levels (p=0.037, OR=0.994; 95%CI 0.988-1.000) were independently associated to PD. TOS correlated with Br-GSH (R=0.34, p=0.037), VM ratio (R=0.43, p=0.015), and neopterin (rho=0.39, p=0.016).

Conclusions: Reduced systemic antioxidant capacity is found in prodromal and overt PD and may represent, in association with olfactory loss and cardiovascular dysautonomia, a useful biomarker for an integrative, early diagnosis of PD.

Citing Articles

Anticancer Activity of Astaxanthin-Incorporated Chitosan Nanoparticles.

Hwang E, Jeong Y, Lee K, Yu Y, Ohk S, Lee S Molecules. 2024; 29(2).

PMID: 38276606 PMC: 10818874. DOI: 10.3390/molecules29020529.


Identifying the potential role of serum miR-20a as a biomarker for olfactory dysfunction in patients with Parkinson's disease.

Liu H, Zhao H, Bao Y, Yang J, Xie H, Huang D Eur Arch Otorhinolaryngol. 2023; 280(10):4509-4517.

PMID: 37258792 DOI: 10.1007/s00405-023-08034-5.


Combined Dopamine and Grape Seed Extract-Loaded Solid Lipid Nanoparticles: Nasal Mucosa Permeation, and Uptake by Olfactory Ensheathing Cells and Neuronal SH-SY5Y Cells.

Trapani A, Castellani S, Guerra L, De Giglio E, Fracchiolla G, Corbo F Pharmaceutics. 2023; 15(3).

PMID: 36986742 PMC: 10059967. DOI: 10.3390/pharmaceutics15030881.


Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation.

Percario S, da Silva Barbosa A, Varela E, Gomes A, Ferreira M, de Nazare Araujo Moreira T Oxid Med Cell Longev. 2020; 2020:2360872.

PMID: 33101584 PMC: 7576349. DOI: 10.1155/2020/2360872.


Development of early diagnosis of Parkinson's disease: Illusion or reality?.

Ugrumov M CNS Neurosci Ther. 2020; 26(10):997-1009.

PMID: 32597012 PMC: 7539842. DOI: 10.1111/cns.13429.